Not long until 6th Feb presentation with illumia...
Plenty of news still due. Buy |
LOL!!!!!!
There are 5 hidden posts from your filtered users. Show hidden posts Manage filters |
Price was hiked upTo 16p this morning since then not many have made any money and highly unlikely it will break out further hence traders are running |
Looking very bad now |
Now getting smashed |
Major dumping nowClose gap at 14p |
Darmz "Filtered" |
Lots of folks selling nowAnd it's nt to sell so some big sells going throughAgl previously has gone to 35pBut wnt this time |
waterloo01 - Illumina are emailing the details of this EACR webinar as we speak. I suspect it'll be very well attended & would expect a mkt reaction to it. |
The presentation of parsortix by illumina and them giving up the slot for it, is highly unusual. If the response us good, and why wouldn't it be, they must have already inked a deeper collaboration deal. Excellent as it could become the accepted gold standard, and a usp that together would be unmatched. |
Dnt worry im watching |
Gone nT to sell fellaNot looking good |
Watch and weep Darmz. This one has form. |
Sold my last lots small profit doesn't look like it's moving up past 16 |
As per my post above the co-marketing of the ‘optimum’; solution is the key here… 90000 illumina machines that may need to be paired with a parsortix machine…. |
Taken from the LSE site....I think they now where this is going... |
And don't forget Menarini whom Angle are targeting. They have the drug Orserdu.https://www.menarini.com/en-us/news/news-detail/european-commission-approves-menarini-groups-orserdu174-elacestrant-for-the-treatment-of-patients-with-er-her2-locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation |
Interview now out. Illumina are very excited... |
'The two companies plan to collaborate further, aiming to refine liquid biopsy techniques for more effective cancer monitoring.
"We are excited at the prospect of combining ANGLE's Parsortix system with Illumina's NGS assays and optimising a workflow that will enable Illumina customers to offer CTC analysis in the future," said Karen Miller, ANGLE's chief scientific officer.++ |
A little competition is a good thing. I strongly suspect Illumina isn't the only interested party. |
timbo003 - 🤞 not yet.
"Illumina has completed 17 acquisitions with an average acquisition amount of $1.33B. Its most active year was 2013, with 4 acquisitions, and it has averaged nearly 1 acquisition per year over the past three years, including 1 in 2024 so far.4 Oct 2024" |
timbo, did any of those Companies present in ILMN's slot at EACR before being taken over ? might be stretching the research prowess |
.......
Who is next?
....... |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
